

Phase 3a Type II Diabetes



Endocrinology



34 countries



109 sites

Innovative Trials' Clinical Enrolment Managers enabled sites to significantly reduce their screen failure rate in this complex study

Background

This study aimed to recruit children and adolescents with Type II diabetes. However, many of these patients remain undiagnosed and so are not actively being treated.

Challenges

- ⬡ Parents often choose to treat their children with approved medications and can be reluctant to consider clinical trials
- ⬡ Sites felt that the Inclusion criteria for this study were very strict, making it more challenging to identify eligible patients for the study
- ⬡ Many patients do not adhere to their medication, exercise and healthy eating routine due to their young age and so sites felt these patients were not suitable candidates to participate in a clinical trial

Solution

- ⬡ Increased education for the patient and their family, emphasising the importance of adhering to exercise, diet, medication routines
- ⬡ Approaching other family members with type 2 diabetes to see if there are any children/grandchildren that may be interested in the trial
- ⬡ Site recruitment calls conducted in local language to establish positive relationship with sites
- ⬡ Encouraged sites to approach schools and school nurses for recruitment

Outcome

- CEMs contacted GP practices and hospitals to extend referral networks in Belgium, Croatia, Hungary, Norway and Sweden
- Approaching schools was the most effective strategy utilised by sites, followed by advertising in the hospital
- Recruitment plans discussed with the Local Trial Managers to increase recruitment globally for the study
- CEM supported sites showed a 181% increase in pre-screening rates following calls
- Sites receiving CEM support on average recruited a higher number of patients than those not supported, with a 20% increase in recruitment rates



Screening rates
3 times higher
for CEM
supported sites

31% reduction
in screen
failure rate



Better
quality
patients



14.5% non-
performing sites
screened at least
1 patient with
CEM support

Contact us

To learn more about how we may help you and your study, please contact us:

Tel: +44 (0) 1707 378581 (UK Headquarters) or +1 866 324 6770 Ext. 9 (US)

Email: info@innovativetrials.co.uk

Alternatively, for more information, please visit our website: www.innovativetrials.co.uk